Zacks Investment Research downgraded shares of Cambrex Corporation (NYSE:CBM) from a hold rating to a sell rating in a report released on Wednesday.
According to Zacks, “Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance enhancers; and polymer systems. “
Several other equities analysts have also recently weighed in on the company. Craig Hallum set a $70.00 price objective on Cambrex Corporation and gave the company a buy rating in a report on Monday. First Analysis boosted their target price on Cambrex Corporation from $54.00 to $66.00 and gave the company an overweight rating in a research note on Tuesday, January 17th. Finally, Stephens set a $61.00 target price on Cambrex Corporation and gave the company a buy rating in a research note on Monday. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Cambrex Corporation presently has an average rating of Buy and a consensus target price of $62.00.
Cambrex Corporation (NYSE:CBM) traded up 0.77% during trading on Wednesday, reaching $52.15. The company had a trading volume of 122,759 shares. The company has a 50 day moving average price of $54.20 and a 200 day moving average price of $48.62. Cambrex Corporation has a 52-week low of $34.63 and a 52-week high of $62.50. The company has a market capitalization of $1.69 billion, a PE ratio of 21.04 and a beta of 1.95.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings data on Friday, February 3rd. The company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.18. Cambrex Corporation had a return on equity of 24.53% and a net margin of 16.65%. The business had revenue of $178.70 million for the quarter, compared to analysts’ expectations of $174.53 million. During the same quarter in the previous year, the business posted $1.01 EPS. Cambrex Corporation’s revenue for the quarter was up 13.9% on a year-over-year basis. On average, equities analysts forecast that Cambrex Corporation will post $2.87 EPS for the current fiscal year.
In other Cambrex Corporation news, insider Gregory Sargen sold 22,500 shares of the business’s stock in a transaction that occurred on Friday, November 11th. The stock was sold at an average price of $52.02, for a total transaction of $1,170,450.00. Following the transaction, the insider now owns 27,500 shares of the company’s stock, valued at approximately $1,430,550. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Shawn Cavanagh sold 20,380 shares of the business’s stock in a transaction that occurred on Tuesday, February 7th. The stock was sold at an average price of $55.12, for a total value of $1,123,345.60. Following the transaction, the chief operating officer now directly owns 57,658 shares in the company, valued at approximately $3,178,108.96. The disclosure for this sale can be found here. Insiders have sold a total of 102,880 shares of company stock worth $5,547,596 in the last ninety days. Insiders own 2.63% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Fiera Capital Corp acquired a new position in Cambrex Corporation during the second quarter worth $23,842,000. Numeric Investors LLC raised its position in Cambrex Corporation by 32.7% in the second quarter. Numeric Investors LLC now owns 32,721 shares of the company’s stock worth $1,693,000 after buying an additional 8,054 shares during the last quarter. EverPoint Asset Management LLC acquired a new position in Cambrex Corporation during the second quarter worth $15,519,000. Tower Research Capital LLC TRC acquired a new position in Cambrex Corporation during the second quarter worth $106,000. Finally, Vanguard Group Inc. raised its position in Cambrex Corporation by 6.5% in the second quarter. Vanguard Group Inc. now owns 2,858,572 shares of the company’s stock worth $147,874,000 after buying an additional 175,578 shares during the last quarter. 98.60% of the stock is currently owned by institutional investors and hedge funds.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Get a free copy of the Zacks research report on Cambrex Corporation (CBM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com